Capecitabine-Induced Hypertriglyceridemia and Hyperglycemia: Two Cases


Duman B. B. , PAYDAŞ S. , Tetiker T. , Gunaldi M., Afsar C. U. , Ercolak V., ...Daha Fazla

PHARMACOLOGY, cilt.90, ss.212-215, 2012 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 90
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1159/000342382
  • Dergi Adı: PHARMACOLOGY
  • Sayfa Sayıları: ss.212-215

Özet

Capecitabine has shown significant antitumor activity against anthracycline/taxane refractory breast cancer and advanced colorectal carcinoma. The main drug-related adverse effects are palmar-plantar erythrodysesthesia (handfoot syndrome), diarrhea and stomatitis. Dyslipidemia is a rare but important side effect of this drug. The mechanism of capecitabine-induced hypertriglyceridemia (CI-HTG) is unclear. It may be due to the decreased activities of lipoprotein lipase and hepatic triglyceride lipase. This report is associated with 2 patients who developed severe HTG when receiving capecitabine. Capecitabine was discountinued and antilipemic treatments were given and both cases are in follow-up with normal lipid levels. This report describes CI-HTG and possible pathogenetic mechanisms and the literature is reviewed. Copyright (c) 2012 S. Karger AG, Basel